Chinese biotech developing toripalimab, a PD-1 cancer immunotherapy antibody approved in China and the US (as Loqtorzi via partner Coherus).
Chinese biotech developing toripalimab, a PD-1 cancer immunotherapy antibody approved in China and the US (as Loqtorzi via partner Coherus).
Sells toripalimab to Chinese hospitals, where a place on the national reimbursement list opens volume at lower prices, and earns licence fees and milestone payments from partners abroad: Coherus holds the US and Canada rights under a 2021 deal. Heavy spending on trials and the antibody pipeline makes partner payments a second income stream.
In one line: A Chinese immuno-oncology biotech, akin to a smaller BeiGene.
Moat: narrow (IP / patents, regulatory licence). First Chinese-developed PD-1 antibody approved in the US, protected by patents and regulatory approvals.
Headquarters: Shanghai, China · Founded: 2012 · Employees: 2,903
Size Shanghai Junshi Biosciences (688180.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.48B, the 701st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.63 on 18 Nov 2026.
Performance Over six months the shares fell 30.9%, against +8.1% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue grew 29.1% over the last twelve months (peer median +7.9%); the operating margin is -14.6% (peer median 12.2%).
Valuation It trades at 8.1× enterprise value to sales against a peer median of 3.1× (4th most expensive of 16).
Capital Return on invested capital runs 7.0 points below its cost of capital (5.0% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.21B | CN¥2.49B | CN¥1.94B | CN¥1.50B | CN¥1.45B |
| Revenue growth | — | +28% | +30% | +3% | — |
| Gross profit | CN¥2.75B | CN¥1.81B | CN¥1.31B | CN¥714M | CN¥718M |
| EBITDA | n/a | -CN¥615M | -CN¥1.01B | -CN¥2.18B | -CN¥2.45B |
| Net income | -CN¥429M | -CN¥875M | -CN¥1.28B | -CN¥2.28B | -CN¥2.39B |
| Free cash flow | -CN¥748M | -CN¥1.25B | -CN¥2.07B | -CN¥2.73B | -CN¥2.11B |
| Capital expenditure | CN¥787M | CN¥768M | CN¥691M | CN¥833M | CN¥394M |
| Total debt | CN¥6.82B | CN¥4.14B | CN¥2.93B | CN¥1.79B | CN¥1.32B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Shanghai Junshi Biosciences 688180.SS | $3.48B | -31% | +29% | -15% | 8.1× | n/a |
| BeOne Medicines 688235.SS | $45.5B | +9% | +25% | 18% | 6.3× | 19.1% |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 7.3× | 11.6% |
| Merck & MRK | $340B | +23% | +5% | 18% | 5.7× | 8.3% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 8.0× | 13.4% |
| Akeso 9926.HK | $7.01B | -48% | +42% | -25% | 12.9× | n/a |
| Shanghai Henlius Biotech 2696.HK | $3.05B | -39% | +33% | 12% | 3.3× | 14.1% |
| CStone Pharmaceuticals 2616.HK | $1.21B | -22% | +117% | -89% | 17.0× | n/a |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688180.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.4% | +4.5% | 2nd lowest of 21 |
| 6-month return | -30.9% | +8.1% | 2nd lowest of 20 |
| Distance from 52-week high | -42.8% | -18.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | +29.1% | +7.9% | 5th highest of 18 |
| Operating margin | -14.6% | 12.2% | 2nd lowest of 16 |
| EV / Sales | 8.1× | 3.1× | 4th most expensive of 16 |
| ROIC minus cost of capital | -7.0 pp | +4.3 pp | 5th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | 8.1× | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 3.1× | -2.1% | +12.0% |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 6.6× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 20.4× | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 2.8× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | 9.3× | 58.0% | +4.2% |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | 106.6× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 2.6× | -3.4% | +10.6% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 3.8× | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 2.5× | 4.7% | +4.5% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 0.6× | -4.9% | +7.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 3.2× | 6.4% | +5.9% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 1.8× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 0.3× | -10.0% | +5.4% |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 2.3× | -7.0% | +2.0% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | 5.2× | 34.7% | +159.5% |